HOUSE_OVERSIGHT_028416

i"}, {"range™: {"length":394,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role": "body", "text":"An examination of Celgened€™s aggressive promotion of Revlimid and its predecessor, Thalomid, while Mr. Hugin was a top executive at the company, including its chief executive for six years, reveals many of the controversial financial and legal tactics that have tarnished the industryd€™s reputation, from marketing drugs for unapproved uses to raising prices and fighting off generic competitors.", "type": "text"}, ("additions": [{"URL":"https://www.nytimes.com/2017/07/25/h ealth/celgene-to-pay-280-million-to-settle-fraud-suit-over-cancer- drugs. html ?partner=applenewsé&ad- keywords=APPLEMOBILE&region=written throughéasset_id=100000006090758", "range": {"length" 793, "start":19},"type™:"Link"}],"identifier":" anf-body- 12","inlineTextStyles":[{"range":{"length":362,"start":0},"textStyle":" anf-ts- I"},{"range™: {"length":362,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role": "body", "text"™:"Last year, Celgene paid $280 million to settle a whistle- blower lawsuit claiming it had inappropriately promoted Revlimid and Thalomid to treat a range of cancers beyond what the Food and Drug Administration had approved. Several generic drug companies have sued the company claiming that Celgene denied them access to drug samples needed to make cheaper copies.","type™:"text"}, {"additions": [{"URL":"https://www. youtube.com/watch?v=RIfséhthw Go", "range": {"length":71,"start":138},"type":"link"}],"identifier":" anf-body- 13","inlineTextStyles":[{"range":{"length":334,"start":0},"textStyle":" anf-ts- i"},{"range™: {"length":334,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role": "body", "text":"Mr. Hugin has also been targeted by a super PAC run by a cancer patient taking Revlimid that launched a $1.5 million advertising campaign criticizing steep price hikes of cancer drugs during Mr. Hugind€™s tenure at Celgene. And the Mene